Artiva Biotherapeutics (ARTV) Operating Income (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Operating Income data on file, last reported at -$24.4 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$24.4 million, down 10.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$92.1 million (down 22.82% YoY), and the FY2025 annual result was -$89.8 million, down 33.48% from the prior year.
• Operating Income eased to -$24.4 million in Q1 2026 per ARTV's latest filing, from -$21.9 million in the prior quarter.
• Over five years, Operating Income peaked at $12.7 million in Q4 2023 and troughed at -$24.4 million in Q1 2026.
• A 4-year average of -$14.2 million and a median of -$18.3 million in 2024 frame the typical range for Operating Income.
• The sharpest annual moves came in 2024 and 2026: Operating Income slumped 269.6% in 2024, then dropped 10.19% in 2026.
• A 4-year view of Operating Income shows it stood at $12.7 million in 2023, then plunged by 244.2% to -$18.3 million in 2024, then decreased by 20.06% to -$21.9 million in 2025, then slipped by 11.39% to -$24.4 million in 2026.
• Business Quant data shows ARTV's Operating Income at -$24.4 million in Q1 2026, -$21.9 million in Q4 2025, and -$22.9 million in Q3 2025.